The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).

Shares of Omeros touched a 52-week high, a day after the company said it could resubmit its biologics license application for narsoplimab to the Food and Drug Administration. In Thursday afternoon ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports ...

Neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic indicator in myeloproliferative neoplasms, correlating with ...

DelveInsight's D-Dimer Testing Market Insights report provides the current and forecast market analysis, individual leading D ...

“This connection may involve genetic factors that influence how the body responds to the virus and its aftermath, ...

The patient had been suffering from hard-to-control diabetes despite intensive insulin treatment and had received a pancreas ...

Good afternoon and welcome to today's conference call for Omeros Corporation. (Operator Instructions) Please be advised that this call is being recorded at the company's request and a replay will be ...

As described in previous updates, we have been working closely with FDA regarding the anticipated resubmission of our Biologics License Application, or BLA for narsoplimab in hematopoietic stem cell ...